Didanosine hypertension

APV, amprenavir ATV, atazanavir CNS, central nervous system CVD, cardiovascular disease D/C, discontinue ddC, zalcitabine ddl, didanosine DEXA, dual-energy x-ray absorptiometry d4T, stavudine EFV, efavirenz HDL, high-density lipoprotein HIV, human immunodeficiency virus HTN, hypertension IDV, indinavir LDL, low-density lipoprotein LPV/r, lopinavir+ ritonavir MRI, magnetic resonance imaging NNRTI, nonnucleoside reverse transcriptase inhibitor NRTI, nucleoside reverse transcriptase inhibitor NVP, nevirapine PI, protease inhibitor RTV, ritonavir SQV, saquinavir TDF, tenofovir disoproxil fumarate TG, triglyceride TPV/r, tipranivir + ritonavir ZDV, zidovudine. [Pg.1273]

NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS ANTI HYPERTENSIVES AND HEART FAILURE DRUGS-VASODILATOR ANTI HYPERTENSIVES Risk of peripheral neuropathy when hydralazine is co-administered with didanosine, stavudine or zalcitabine Additive effect both drugs can cause peripheral neuropathy Warn patients to report early features of peripheral neuropathy if this occurs, the nucleoside reverse transcriptase inhibitor should be stopped... [Pg.607]

Liver Long-term didanosine therapy was associated with non-cirrhotic portal hypertension in three HIV-positive individuals with chronic hepatitis C, mild liver fibrosis, and... [Pg.587]

In a nested case-control study conducted by the Swiss HIV Cohort there was a strong association between prolonged exposure to didanosine and non-cirrhotic portal hypertension [107 ]. In 15 patients with non-cirrhotic portal hypertension and 75 controls matched for duration of HIV infection, absence of viral hepatitis, and duration of follow-up, cumulative exposure to antiretroviral drug therapy (OR per year = 1.3 95% Cl = 1.0,1.6), nucleoside reverse transcriptase inhibitors (OR = 1.3 95% Cl = 1.1, 1.7), didanosine (OR = 3.4 95% Cl = 1.5, 8.1), ritonavir (OR = 1.4 95% Cl = 1.0, 1.9), and nelfinavir (OR = 1.4 95% Cl = 1.0,1.9) were longer in the patients with portal hypertension. Exposure to non-nucleoside reverse transcriptase inhibitors and other protease inhibitors were not different. [Pg.587]

Liver A further case of non-cirrhotic portal hypertension has been reported with didanosine [152 ]. [Pg.416]

Chang HM, Tsai HC, Lee SS, Warm SR, Chen YS. Noncirrhotic portal hypertension associated with didanosine a case report and literature review. Jpn J Infect Dis 2012 65(l) 61-5. [Pg.437]